[关键词]
[摘要]
糖尿病视网膜病变(DR)作为糖尿病最常见的微血管并发症,已成为各年龄段人群视力损害的首要致盲因素。DR的早期诊断与严重程度评估依赖于对视网膜微血管的精准检测。动脉周围无毛细血管区(paCFZ)作为视网膜动脉周围的生理性无血管区域,近年来被认为是反映视网膜微循环状态的重要生物标志物。随着光学相干断层扫描血管成像(OCTA)技术的快速发展,paCFZ得以实现无创、高分辨率的定量测量,为DR的早期识别与分期提供了新的监测指标。文章系统综述了paCFZ的定义、形成机制及其在DR各阶段的形态变化特征,重点探讨了OCTA在paCFZ可视化与量化分析中的应用优势,包括其在非增殖期DR与增殖期DR中的差异表现及其与视网膜缺血、氧合状态的关系。此外文章还总结了paCEZ在评估抗VEGF治疗反应及预测疾病进展方面的潜力,并指出当前临床转化中面临的挑战与未来研究方向,旨在为DR的早期筛查、风险分层及个体化治疗提供理论依据与新思路。
[Key word]
[Abstract]
Diabetic retinopathy(DR), the most common microvascular complication of diabetes, has become a leading cause of visual impairment and blindness across all age groups. The early diagnosis and severity assessment of DR rely on the precise evaluation of retinal microvascular alterations. The periarterial capillary-free zone(paCFZ), a physiological avascular region surrounding retinal arteries, has recently been recognized as an important biomarker reflecting the status of retinal microcirculation. Advances in optical coherence tomography angiography(OCTA)have enabled noninvasive, high-resolution quantification of the paCFZ, offering a novel approach for the early detection and stratification of DR. This review systematically summarizes the definition and developmental mechanism of the paCFZ, as well as its morphological characteristics across different stages of DR, with a particular focus on the advantages of OCTA in visualizing and quantifying the paCFZ. We further discuss the differential manifestations of the paCFZ in nonproliferative DR and proliferative DR, and its associations with retinal ischemia and oxygenation status. In addition, the potential clinical value of paCFZ in evaluating responses to anti-vascular endothelial growth factor(VEGF)therapy and predicting disease progression is summarized. Finally, the challenges in clinical translation and future research directions are addressed, aiming to provide theoretical support and new perspectives for early screening, risk stratification, and personalized management of DR.
[中图分类号]
[基金项目]
河南省研究生教育改革与质量提升工程项目(No.YJS2025AL51)